Fulton Breakefield Broenniman’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.1M Sell
30,562
-25
-0.1% -$25.3K 1.83% 16
2025
Q4
$32.9M Sell
30,587
-9,001
-23% -$8.61M 2.07% 15
2025
Q3
$30.2M Sell
39,588
-901
-2% -$670K 1.95% 15
2025
Q2
$31.6M Sell
40,489
-143
-0.4% -$111K 2.13% 15
2025
Q1
$33.6M Sell
40,632
-2,008
-5% -$1.67M 2.42% 12
2024
Q4
$32.9M Sell
42,640
-75
-0.2% -$62.1K 2.35% 11
2024
Q3
$37.8M Sell
42,715
-965
-2% -$868K 2.64% 11
2024
Q2
$39.5M Sell
43,680
-248
-0.6% -$198K 2.92% 7
2024
Q1
$34.2M Sell
43,928
-12,056
-22% -$8.58M 2.63% 10
2023
Q4
$32.6M Sell
55,984
-653
-1% -$381K 2.63% 10
2023
Q3
$30.4M Sell
56,637
-806
-1% -$415K 2.64% 9
2023
Q2
$26.9M Sell
57,443
-11,233
-16% -$4.71M 2.23% 12
2023
Q1
$23.6M Sell
68,676
-1,055
-2% -$356K 2.03% 13
2022
Q4
$25.5M Buy
69,731
+112
+0.2% +$39.7K 2.26% 11
2022
Q3
$22.5M Sell
69,619
-10,748
-13% -$3.41M 2.11% 13
2022
Q2
$26.1M Sell
80,367
-8,476
-10% -$2.54M 2.25% 9
2022
Q1
$25.4M Buy
88,843
+1,185
+1% +$305K 2.24% 12
2021
Q4
$24.2M Buy
87,658
+1,455
+2% +$369K 1.79% 18
2021
Q3
$19.9M Sell
86,203
-551
-0.6% -$136K 1.71% 21
2021
Q2
$19.9M Sell
86,754
-41,242
-32% -$8.28M 1.7% 23
2021
Q1
$23.9M Buy
127,996
+22,721
+22% +$4.44M 2.21% 12
2020
Q4
$17.8M Sell
105,275
-15,425
-13% -$2.3M 2.13% 13
2020
Q3
$17.9M Buy
120,700
+24,443
+25% +$3.78M 2.01% 19
2020
Q2
$15.8M Buy
96,257
+3,750
+4% +$576K 1.92% 21
2020
Q1
$12.8M Buy
92,507
+3,029
+3% +$416K 1.92% 20
2019
Q4
$11.8M Buy
89,478
+1,055
+1% +$122K 1.37% 31
2019
Q3
$9.89M Buy
+88,423
New +$9.84M 1.26% 42

Other funds holding LLY

Fulton Breakefield Broenniman's LLY Position: Q1 2026 in Review

Fulton Breakefield Broenniman reduced its Eli Lilly (LLY) stake by 0.08% in Q1 2026, selling an estimated $25.3K and leaving 30,562 shares worth $28.1M. The position accounts for 1.83% of the portfolio, ranked #16.

Fulton Breakefield Broenniman first reported a position in LLY in Q3 2019 and has held it in 27 quarters since. The position peaked at $39.5M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Fulton Breakefield Broenniman held 30,562 shares of Eli Lilly worth $28.1M as of Q1 2026.
  • Fulton Breakefield Broenniman sold 25 Eli Lilly shares in Q1 2026, an estimated $25.3K.
  • Eli Lilly made up 1.83% of Fulton Breakefield Broenniman's portfolio in Q1 2026, its #16 holding.
  • Fulton Breakefield Broenniman first reported a position in Eli Lilly in Q3 2019 and has held it in 27 quarters since.
  • Fulton Breakefield Broenniman's Eli Lilly position peaked at $39.5M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Fulton Breakefield Broenniman's 13F filing for Q1 2026, filed 27 Apr 2026.